Hypervision Surgical (HVS), a pioneer in real-time hyperspectral imaging for surgery has announced the closure of its Series A financing round after successfully raising £17 million to progress its UK-certified and FDA-cleared HYPERSNAP® system.
Led by Heal Capital with participation from Angelini Ventures, IP Group and Daycrest, the round also includes follow-on investment from HEARN Partners, Redalphine, LifeX Ventures and ZEISS Ventures, as well as strategic investment from SAGES Ingenuity – the for-profit innovation arm of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and Macmillan Cancer Support, the UK’s leading cancer charity.
A King’s College London spinout working as part of the London Institute for Healthcare Engineering (LIHE) and St Thomas’ MedTech ecosystem, Hypervision was founded by Dr Michael Ebner, a King’s post-doctoral researcher at the time, Tom Vercauteren, Professor of Interventional Image Computing, Jonathan Shapey, Clinical Reader and Professor Sebastien Ourselin FREng FMedSci, Head of School of Biomedical Engineering & Imaging Sciences.
The company will use the funding to accelerate commercial deployment and expand clinical adoption of its next generation hyperspectral sensing technologies.
Michael Ebner, CEO and Co-Founder, Hypervision Surgical, said: “This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery—giving surgeons real-time insights into tissue that were previously impossible to access.”
Hyperspectral imaging uses light-matter interactions between wavelengths and biological materials to reveal what the naked eye cannot – including important tissue health characteristics such as composition and blood oxygenation.
The technology aims to break down visual limitations for surgeons, who despite advances in digital and robotic surgery still mostly rely on sight examination to guide important intraoperative decisions, potentially improving clinical decision-making and tissue health diagnosis during operations.
Christian Lautner, Founding Managing Partner, Heal Capital, said: “Surgical AI has made impressive progress using conventional cameras, but it ultimately faces a ceiling—it captures how tissue looks, not what is happening beneath the surface. Hypervision removes that limitation by delivering real-time, quantitative insights into tissue physiology at the pixel level. We believe this represents the sensing layer on which the next generation of surgical systems will be built—one that will make surgery measurably safer. That’s why we are proud to lead this round.”
Hyperspectral Intelligence® is Hypervision’s platform technology. It combines proprietary on-chip spectral sensing, patented AI analytics, and a cloud-scalable architecture. Together, these technologies transform surgical imaging into real-time, data-driven decision support, generating previously invisible pixel-level insights into tissue physiology and composition during surgery.
Hyperspectral Intelligence®: A new layer of surgical intelligence. Hypervision’s spectral chip and AI seamlessly integrate into existing vision systems, delivering quantitative tissue insights beyond conventional, subjective vision. As a software-centric solution, it enables scalable, data-driven decision support – adding an objective layer of intelligence during surgery.
HYPERSNAP©, is the initial clinical deployment of Hyperspectral Intelligence® and Hypervision’s first commercial surgical system. It is designed to bring high-performance edge computing capabilities to power real-time reasoning in the operating theatre. The technology is certified in the UK and cleared by the US FDA for open and minimally-invasive general surgery.
HYPERSNAP®, Hypervision’s first commercial surgical system, shown here in an operating theatre environment, represents the initial clinical deployment of the Hyperspectral Intelligence® platform — a fully certified laparoscopic vision stack designed for seamless integration into surgical workflows. It is certified for use in open and minimally invasive general surgery in both the UK and the USA.
Hypervision’s Series A funding will be used to build on the learnings gained from over 170 surgical procedures conducted across three UK NHS trusts so far. St Thomas’ Hospital has been a major contributor to the clinical evaluation of HYPERSNAP, with more than 60 colorectal procedures performed, including the very first. The funding will also be used to help expand use across more UK, European and US sites.
The funding will also advance development of the company’s next-generation hyperspectral sensing technology – co-developed with imec, a global leader in semiconductor and spectral sensing technologies – towards a scalable, cloud-enabled surgical intelligence platform.
The St Thomas’ MedTech ecosystem – including LIHE, the Surgical & Interventional Engineering Research Centre and St Thomas’ Hospital – has been instrumental to Hypervision’s commercial success with Ebner saying it helped to “reduce barriers to complex surgical device development, significantly accelerating product development and clinical evaluation cycles”.
Sir Bashir M. Al-Hashimi, Vice President (Research & Innovation), King’s College London, said: “Hypervision is an excellent example of how ecosystems, like the London Institute for Healthcare Engineering and St Thomas’ Medtech hub, work to accelerate the translation of innovative research into commercial successes with human benefits. I am excited to watch Hypervision build on the progress of its surgical innovations as it works towards widespread clinical adoption.”